Log in

NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, Forecast & News

-0.06 (-5.94 %)
(As of 02/28/2020 02:58 AM ET)
Today's Range
Now: $0.95
50-Day Range
MA: $1.36
52-Week Range
Now: $0.95
Volume104,800 shs
Average Volume40,226 shs
Market Capitalization$7.05 million
P/E RatioN/A
Dividend YieldN/A
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANCN



Sales & Book Value

Annual SalesN/A


Net Income$-13,280,000.00


Market Cap$7.05 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions

What is ANCHIANO THERAP/S's stock symbol?

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

How were ANCHIANO THERAP/S's earnings last quarter?

ANCHIANO THERAP/S (NASDAQ:ANCN) released its earnings results on Monday, August, 5th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.12. View ANCHIANO THERAP/S's Earnings History.

When is ANCHIANO THERAP/S's next earnings date?

ANCHIANO THERAP/S is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for ANCHIANO THERAP/S.

What price target have analysts set for ANCN?

3 analysts have issued twelve-month price targets for ANCHIANO THERAP/S's shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate ANCHIANO THERAP/S's stock price to reach $14.00 in the next year. This suggests a possible upside of 1,373.7% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S.

What is the consensus analysts' recommendation for ANCHIANO THERAP/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ANCHIANO THERAP/S.

Has ANCHIANO THERAP/S been receiving favorable news coverage?

Media stories about ANCN stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ANCHIANO THERAP/S earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for ANCHIANO THERAP/S.

Who are some of ANCHIANO THERAP/S's key competitors?

What other stocks do shareholders of ANCHIANO THERAP/S own?

Who are ANCHIANO THERAP/S's key executives?

ANCHIANO THERAP/S's management team includes the folowing people:
  • Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)
  • Mr. Jonathan Burgin, CFO & COO (Age 58)
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)
  • Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41)


(ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are ANCHIANO THERAP/S's major shareholders?

ANCHIANO THERAP/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Meitav Dash Investments Ltd. (5.01%).

Which institutional investors are selling ANCHIANO THERAP/S stock?

ANCN stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd..

How do I buy shares of ANCHIANO THERAP/S?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ANCHIANO THERAP/S's stock price today?

One share of ANCN stock can currently be purchased for approximately $0.95.

How big of a company is ANCHIANO THERAP/S?

ANCHIANO THERAP/S has a market capitalization of $7.05 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S.

What is ANCHIANO THERAP/S's official website?

The official website for ANCHIANO THERAP/S is http://www.anchiano.com/.

How can I contact ANCHIANO THERAP/S?

ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected]

MarketBeat Community Rating for ANCHIANO THERAP/S (NASDAQ ANCN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  55 (Thanks for Voting!)
Underperform Votes:  55 (Thanks for Voting!)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote "Outperform" if you believe ANCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel